2016 AGENDA AT A GLANCE

 

Across two days in May, World Biosimilar Congress USA 2017 will gather together top biopharma to tackle common barriers in accessing the US biosimilars market such as high development costs, time-consuming R&D, and lengthy clinical trials. We're still working on our 2017 agenda, so we've included a look at what World Biosimilar Congress USA had to offer last year! 

 

In 2016, we were joined by experts from across the biosimilars industry to discuss:

 

 

COMPETING IN THE BIOSIMILARS MARKET: PERSPECTIVE FROM A PURE PLAY COMPANY

  • What are the myths and realities about biosimilars?
  • How can we increase understanding of biosimilars among physicians, patients, and other key stakeholders?
  • Why do biosimilars require a paradigm shift in our approach to evaluating clinical data?

 

BIOSIMILARS ON THE HORIZON: OPPORTUNITIES AND CHALLENGES IN THE UNITED STATES

  • Determining risk of anaphylaxis, autoimmunity, and anti-drug antibodies
  • Assessing impact of subtle recognized differences in quality attributes extrapolated over time, and across a heterogeneous population
  • Exploring the utility of models in the science of comparison in the context of difficult challenges in biosimilar development

 

COMPLEX BIOLOGICAL MODELS IN BIOSIMILAR DEVELOPMENT

  • Determining risk of anaphylaxis, autoimmunity, and anti-drug antibodies
  • Assessing impact of subtle recognized differences in quality attributes extrapolated over time, and across a heterogeneous population
  • Exploring the utility of models in the science of comparison in the context of difficult challenges in biosimilar development

 

THE EVOLVING BIOSIMILAR SECTOR: TRENDS AND IMPLICATIONS

  • Are biosimilars a new pharmaceutical sector?
  • How might the emerging global trends with payers and regulators shape biosimilar development and commercialization?
  • Operational considerations for biosimilars   

 

DOWNLOAD PROSPECTUS

 

Get involved

If you'd like to become an exhibitor or sponsor at the event,
contact Hayim Feuer
on tel: +1 646 619 1789 or hayim.feuer@terrapinn.com